Form 4: CFO Broadfoot Reports RSU Vesting, Tax-Related Stock Sale

aTyr Pharma's CFO, Jill Marie Broadfoot, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Jill Marie Broadfoot, Chief Financial Officer of aTYR PHARMA INC, reported changes in her beneficial ownership.
• On February 3, 2026, 3,750 shares of Common Stock were acquired due to the vesting of Restricted Stock Units (RSUs) granted on February 3, 2022.
• Following this acquisition, the total amount of Common Stock beneficially owned was 38,854 shares.
• On February 4, 2026, 1,558 shares of Common Stock were disposed of (sold) at a price of $0.976 per share.
• This sale was conducted to satisfy tax withholding obligations associated with the partial vesting of the RSUs.
• After the sale, the reporting person beneficially owned 37,296 shares of Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a sale, it's for tax purposes following RSU vesting, which is a normal part of executive compensation and indicates the executive is receiving their earned equity.

Positives

• The vesting of 3,750 Restricted Stock Units indicates the fulfillment of long-term incentive compensation for the Chief Financial Officer.
• The transaction demonstrates continued alignment of management's interests with shareholders through equity ownership.

Negatives

• A sale of 1,558 shares, even for tax purposes, reduces the direct equity stake of the Chief Financial Officer.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the scheduled vesting of RSUs.

Industry Context

StockSavvy.ai notes that routine insider transaction filings like Form 4 are common across all industries, particularly for executive equity compensation plans. The sale of shares to cover tax obligations upon RSU vesting is a standard practice and generally not indicative of a change in management's long-term view of the company, unless the sale volume is unusually high or not tax-related.

Comparison to Industry Standards

• This type of transaction, where executives sell a portion of vested equity to cover tax liabilities, is a standard practice in public companies across various sectors, including biotechnology.
• For instance, executives at companies like Biogen or Amgen frequently engage in similar tax-related sales upon equity award vesting.
• The reported sale of 1,558 shares out of 3,750 vested shares (approximately 41.5%) for tax purposes is within typical ranges for income tax and social security contributions on equity compensation.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not indicate a significant shift in company strategy or financial health. The sale for tax purposes is common and not typically a signal of lack of confidence.
• Employees: The vesting of RSUs for a key executive reinforces the company's compensation structure for its leadership.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are standard for executive compensation and do not typically provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific filing.

Keywords

aTYR Pharma, ATYR, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, CFO, Jill Marie Broadfoot, Equity Compensation, Tax Withholding